Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2005 Feb;42(2):98–102. doi: 10.1136/jmg.2004.024802

Milroy disease and the VEGFR-3 mutation phenotype

G Brice 1, A Child 1, A Evans 1, R Bell 1, S Mansour 1, K Burnand 1, M Sarfarazi 1, S Jeffery 1, P Mortimer 1
PMCID: PMC1735984  PMID: 15689446

Abstract

Primary congenital lymphoedema (Milroy disease) is a rare autosomal dominant condition for which a major causative gene defect has recently been determined. Mutations in the vascular endothelial growth factor receptor 3 (VEGFR-3) gene have now been described in 13 families world-wide. This is a review of the condition based on the clinical findings in 71 subjects from 10 families. All 71 individuals have a mutation in VEGFR-3. Ninety per cent of the 71 individuals carrying a VEGFR-3 mutation showed signs of oedema, which was confined in all cases to the lower limbs. In all but two cases onset of swelling was from birth. Other symptoms and signs included cellulitis (20%), large calibre leg veins (23%), papillomatosis (10%), and upslanting toenails (10%). In males, hydrocoele was the next most common finding after oedema (37%). Thorough clinical examination of these patients indicates that there are few clinical signs in addition to lower limb oedema. Rigorous phenotyping of patients produces a high yield of VEGFR-3 mutations.

Full Text

The Full Text of this article is available as a PDF (155.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell R., Brice G., Child A. H., Murday V. A., Mansour S., Sandy C. J., Collin J. R., Brady A. F., Callen D. F., Burnand K. Analysis of lymphoedema-distichiasis families for FOXC2 mutations reveals small insertions and deletions throughout the gene. Hum Genet. 2001 Jun;108(6):546–551. doi: 10.1007/s004390100528. [DOI] [PubMed] [Google Scholar]
  2. Bollinger A., Isenring G., Franzeck U. K., Brunner U. Aplasia of superficial lymphatic capillaries in hereditary and connatal lymphedema (Milroy's disease). Lymphology. 1983 Mar;16(1):27–30. [PubMed] [Google Scholar]
  3. Brice G., Mansour S., Bell R., Collin J. R. O., Child A. H., Brady A. F., Sarfarazi M., Burnand K. G., Jeffery S., Mortimer P. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet. 2002 Jul;39(7):478–483. doi: 10.1136/jmg.39.7.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dumont D. J., Jussila L., Taipale J., Lymboussaki A., Mustonen T., Pajusola K., Breitman M., Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 1998 Oct 30;282(5390):946–949. doi: 10.1126/science.282.5390.946. [DOI] [PubMed] [Google Scholar]
  5. Evans A. L., Bell R., Brice G., Comeglio P., Lipede C., Jeffery S., Mortimer P., Sarfarazi M., Child A. H. Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema. J Med Genet. 2003 Sep;40(9):697–703. doi: 10.1136/jmg.40.9.697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Evans A. L., Brice G., Sotirova V., Mortimer P., Beninson J., Burnand K., Rosbotham J., Child A., Sarfarazi M. Mapping of primary congenital lymphedema to the 5q35.3 region. Am J Hum Genet. 1999 Feb;64(2):547–555. doi: 10.1086/302248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fang J., Dagenais S. L., Erickson R. P., Arlt M. F., Glynn M. W., Gorski J. L., Seaver L. H., Glover T. W. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet. 2000 Nov 8;67(6):1382–1388. doi: 10.1086/316915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ferrell R. E., Levinson K. L., Esman J. H., Kimak M. A., Lawrence E. C., Barmada M. M., Finegold D. N. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum Mol Genet. 1998 Dec;7(13):2073–2078. doi: 10.1093/hmg/7.13.2073. [DOI] [PubMed] [Google Scholar]
  9. Holberg C. J., Erickson R. P., Bernas M. J., Witte M. H., Fultz K. E., Andrade M., Witte C. L. Segregation analyses and a genome-wide linkage search confirm genetic heterogeneity and suggest oligogenic inheritance in some Milroy congenital primary lymphedema families. Am J Med Genet. 2001 Feb 1;98(4):303–312. doi: 10.1002/1096-8628(20010201)98:4<303::aid-ajmg1113>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  10. Irrthum A., Karkkainen M. J., Devriendt K., Alitalo K., Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet. 2000 Jun 9;67(2):295–301. doi: 10.1086/303019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Irrthum Alexandre, Devriendt Koenraad, Chitayat David, Matthijs Gert, Glade Conrad, Steijlen Peter M., Fryns Jean-Pierre, Van Steensel Maurice A. M., Vikkula Miikka. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet. 2003 May 8;72(6):1470–1478. doi: 10.1086/375614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Karkkainen M. J., Ferrell R. E., Lawrence E. C., Kimak M. A., Levinson K. L., McTigue M. A., Alitalo K., Finegold D. N. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 2000 Jun;25(2):153–159. doi: 10.1038/75997. [DOI] [PubMed] [Google Scholar]
  13. Karkkainen Marika J., Haiko Paula, Sainio Kirsi, Partanen Juha, Taipale Jussi, Petrova Tatiana V., Jeltsch Michael, Jackson David G., Talikka Marja, Rauvala Heikki. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2003 Nov 23;5(1):74–80. doi: 10.1038/ni1013. [DOI] [PubMed] [Google Scholar]
  14. Levinson Kara L., Feingold Eleanor, Ferrell Robert E., Glover Thomas W., Traboulsi Elias I., Finegold David N. Age of onset in hereditary lymphedema. J Pediatr. 2003 Jun;142(6):704–708. doi: 10.1067/mpd.2003.235. [DOI] [PubMed] [Google Scholar]
  15. Mortimer P. S. Managing lymphedema. Clin Dermatol. 1995 Sep-Oct;13(5):499–505. doi: 10.1016/0738-081x(95)00095-w. [DOI] [PubMed] [Google Scholar]
  16. Mäkinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M. I., Pulkkanen K. J., Kauppinen R., Jackson D. G., Kubo H., Nishikawa S. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001 Feb;7(2):199–205. doi: 10.1038/84651. [DOI] [PubMed] [Google Scholar]
  17. Saaristo Anne, Veikkola Tanja, Tammela Tuomas, Enholm Berndt, Karkkainen Marika J., Pajusola Katri, Bueler Hansruedi, Ylä-Herttuala Seppo, Alitalo Kari. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med. 2002 Sep 16;196(6):719–730. doi: 10.1084/jem.20020587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yoon Young-Sup, Murayama Toshinori, Gravereaux Edwin, Tkebuchava Tengiz, Silver Marcy, Curry Cynthia, Wecker Andrea, Kirchmair Rudolf, Hu Chun Song, Kearney Marianne. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest. 2003 Mar;111(5):717–725. doi: 10.1172/JCI15830. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES